Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study

Table 2 Comparison of changes in serum creatinine and estimated glomerular filtration rate between the tenofovir amibufenamide and tenofovir alafenamide groups.

	TMF group (n = 106)	TAF group (n = 109)	P value
Creatinine (μmol/L)
Before treatment	79.50 (66.05, 91.00)	83.30 (73.00, 93.90)	0.856
After 48 wk	72.00 (63.00, 83.00)	78.10 (61.00, 90.70)	0.194
Reduction	4.00 (-19.65, 19.50)	3.37 (-7.96, 26.13)	0.728
P (baseline vs. 48 wk)	0.053	0.105
eGFR (mL/min/1.73 m2)
Before treatment	90.58 (79.84, 103.80)	97.19 (87.35, 106.38)	0.180
After 48 wk	106.37 (94.58, 113.15)	105.17 (88.15,129.56)	0.617
Reduction	-2.22 (-9.72, 16.75)	-4.17 (-227.89, 7.67)	0.093
P (baseline vs. 48 wk)	0.301	0.108

Data are median M (P25, P75). TMF: Tenofovir amibufenamide; TAF: Tenofovir alafenamide; eGFR: Estimated glomerular filtration rate.